Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France.

METHODS • Schizophrenia is a severe mental disorder, characterized by profound disruptions in thinking and affecting language, perception, and the sense of self.[1] This disabling and emotionally devastating illness is manifested by ‘positive’ (e.g. delusion, hallucinations) and ‘negative’ (e.g. blunted affect, alogia) symptoms. • In 2005, the prevalence of schizophrenia patients in France was estimated between 300,000 and 600,000 people, with an incidence at 10,000 new patients per year.[2-4] • Second generation antipsychotics (or atypical antipsychotics) are recommended as first line by French H.A.S. guidelines, owing to their favourable benefit/risk ratio, whilst first generation antipsychotics (or conventional drugs) are commonly used as second line.[4] Injectable antipsychotics are mainly prescribed in the prevention of relapse because of their improved patient compliance.[4] • This analysis aimed to estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France. • This analysis is the first to assess the cost-effectiveness of antipsychotics based on French observational data.[5] DOUTRIAUX A1, DRUAIS S2, COGNET M1, LANCON C3, SAMALIN L4, LEVY P5, GODET A6, GUILLON P6 1Amaris, London, United Kingdom; 2Amaris, Montreal, Canada; 3Faculty of medicine of Marseille, France; 4CHU Clermont-Ferrand, France; 5University of Dauphine, Paris, France; 6 Janssen Cilag, Issy-lesMoulineaux, France Cost-effectiveness of paliperidone palmitate versus other antipsychotics for the treatment of schizophrenia in France